Regenicin, Inc., headquartered in Little Falls, New Jersey, is a biotechnology company focused on developing regenerative cell therapies to restore the health of damaged tissues and organs. The company has assembled a world-class management team with a proven track record of developing and bringing innovative medical devices and biotechnology products to market.
The company is playing a critical role in the development of the therapeutic candidate, PermaDerm™, a breakthrough technology that uses a patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns and wounds. Using only a postage-stamp biopsy of the patient’s skin, a sheet of PermaDerm™ 100 times the initial size can be grown in as little as 30 days.
PermaDerm™ is being developed to be the only tissue-engineered skin prepared from autologous skin cells consisting of both epidermal and dermal layers. The technology has been clinically tested in more than 150 pediatric, catastrophic burn patients. Currently Regenicin is working with its contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA.
The tissue engineering and cell therapy market is anticipated to grow from $6.9 billion in 2009 to almost $32 billion by 2018 in the U.S. alone, according to MedMarket Diligence. This rapid growth has been primarily attributed to proven clinical benefits, a clearly defined regulatory path, and clinicians’ readiness to adopt these new therapies. With a solid business model in place, Regenicin is positioning itself to become a leader in one of the fastest growing industries in biotechnology.
Let us hear your thoughts: Regenicin, Inc. Message Board